异黏蛋白（MTDH）在转移性乳腺癌中的表达及临床意义

发布时间：2018-10-16 10:29

【摘要】：目的:通过分析异黏蛋白在乳腺癌原发灶、转移灶中表达的情况,及其与乳腺癌生物学特征、生存时间的关系,推测异黏蛋白与乳腺癌的预后的关系。方法:1、选取2008年-2014年间于我院治疗的可获得病理切片的转移性乳腺癌患者共74例。在74例转移性乳腺癌患者中,有26例既有原发灶,又有转移灶。其余的48例中24例只有原发灶,24例只有转移灶。最终获得转移性乳腺癌原发灶组织50例、转移灶组织50例和未发生转移患者的原发灶组织50例,对其行MTDH免疫组化,对MTDH的表达情况进行统计学分析。2、随机选出50名未发生转移的乳腺癌患者,对其原发灶行免疫组化,与上述原发灶MTDH的表达情况进行统计学分析。3、统计患者相关资料,如年龄、月经情况、激素水平、分子分型、肿块大小、淋巴结转移数目、无病生存期、总生存期,分析MTDH的表达与上述资料是否相关。推测MTDH在乳腺癌预后判断中的作用和意义。结果:在50例原发灶及转移灶中,MTDH在原发灶高表达的为37例,低表达为13例,在转移灶中高表达的为46例,低表达为4例(P=0.031)。在26名患者原发灶及转移灶中MTDH均高表达的为18例(69.3%),原发灶低表达转移灶高表达为5例(19.2%),原发灶高表达转移灶低表达为3例(11.5%),均低表达的为0例(0.0%)。在50例转移性乳腺癌和非转移性乳腺癌中,MTDH高表达的分别为24例、37例,低表达的分别为26例、13例(P0.05)。MTDH的表达情况与PR表达(P=0.029)有关。MTDH的表达影响预后,对于总生存期无影响。结论:1、在乳腺癌原发灶中,MTDH高表达,预示容易发生转移;2、PR表达呈阴性的乳腺癌患者,MTDH更倾向于高表达;3、MTDH高表达与转移部位无关;4、在乳腺癌转移灶中,MTDH高表达,它可能成为未来治疗的新靶点;5、MTDH是乳腺癌DFS的独立预后因素,但对于总生存期无影响。
[Abstract]:Objective: to analyze the expression of heteromucin in primary and metastatic lesions of breast cancer, and its relationship with biological characteristics and survival time of breast cancer, and to speculate the relationship between heteromycin and prognosis of breast cancer. Methods: 1. 74 patients with metastatic breast cancer treated in our hospital from 2008 to 2014 were selected. Of 74 patients with metastatic breast cancer, 26 had both primary and metastatic lesions. Of the remaining 48 cases, only primary lesions were found in 24 cases and metastatic lesions in 24 cases. Finally, 50 cases of primary tissues of metastatic breast cancer, 50 cases of metastatic tissues and 50 cases of non-metastatic breast cancer tissues were obtained. MTDH immunohistochemical staining was performed for them. The expression of MTDH was analyzed statistically. 2. 50 patients with breast cancer without metastasis were randomly selected, and their primary lesions were treated with immunohistochemistry. The expression of MTDH in the above primary tumor was analyzed statistically. 3. The relevant data of patients, such as age, were analyzed. Menstruation, hormone level, molecular classification, tumor size, lymph node metastasis, disease-free survival, total survival. The role and significance of MTDH in prognosis of breast cancer were speculated. Results: in 50 cases of primary tumor and metastasis, 37 cases were high expression of MTDH, 13 cases were low expression, 46 cases were high expression and 4 cases were low expression in primary tumor (P0. 031). There were 18 cases (69.3%) with high expression of MTDH, 5 cases (19.2%) with high expression of MTDH, 3 cases (11.5%) with low expression of MTDH and 0 cases (0.00%) with low expression of MTDH. In 50 cases of metastatic breast cancer and non-metastatic breast cancer, the high expression of MTDH was found in 24 cases, 37 cases and the low expression in 26 cases, respectively. The expression of). MTDH was related to the expression of PR (P0. 029) in 13 cases (P0.05). The expression of MTDH affected the prognosis, but had no effect on the overall survival time. Conclusion: 1, in primary breast cancer, the high expression of MTDH indicates that it is easy to metastasize; 2in breast cancer patients with negative PR expression, MTDH is more likely to be overexpression; 3MTDH high expression is not related to the location of metastasis; 4, in breast cancer metastasis, MTDH is highly expressed. MTDH is an independent prognostic factor for breast cancer DFS, but has no effect on overall survival.
【学位授予单位】：吉林大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R737.9

【参考文献】